Vertex Pharmaceuticals Incorporated: shareholders and insiders

VRTXNASDAQHealthcare · Pharmaceutical Preparations

Price

$538.60

November 13, 2026Market cap $137B

What Ploutos Investor adds for Vertex Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 16, 2025 to Nov 10, 2026, from their own Form 4 filings.

20 Form 4s

Bought on the market

–

nobody

Sold on the market

$132M

13 people

From Nov 16, 2025 to Nov 16, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan100%
  • The rest0%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 16, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $94M by 12 people

  • 2025: no buys, sold $38M by 5 people
  • 2026: no buys, sold $94M by 12 people
  • Nov 6, 2026Reshma KewalramaniCEO & President
    Kind10b5-1
  • Oct 20, 2026Daniel J. BrennanDirector
    Kind
  • Sep 8, 2026Grunsven Jasper vanEVP, CP and NPPO
    Kind
  • Aug 28, 2026Kristen AmbroseSVP & Chief Accounting Officer
    Kind
  • Aug 27, 2026Bruce I SachsDirector
    Kind
  • Jul 21, 2026Ourania TatsisEVP, Chief Reg. & Quality Off.
    Kind
  • Jul 21, 2026Amit SachdevEVP Chief Patient & Ext Af Off
    Kind
  • Jul 2, 2026Ourania TatsisEVP, Chief Reg. & Quality Off.
    Kind10b5-1
  • Jul 2, 2026Duncan McKechnieEVP, Chief Commercial Officer
    Kind10b5-1
  • Jul 1, 2026Joy LiuEVP and Chief Legal Officer
    Kind10b5-1
  • Jun 26, 2026Carmen BozicEVP and CMO
    Kind10b5-1
  • Jun 18, 2026Carmen BozicEVP and CMO
    Kind10b5-1
  • Jun 15, 2026Carmen BozicEVP and CMO
    Kind10b5-1
  • Jun 5, 2026Carmen BozicEVP and CMO
    Kind10b5-1
  • Jun 1, 2026Joy LiuEVP and Chief Legal Officer
    Kind10b5-1
  • May 29, 2026Carmen BozicEVP and CMO
    Kind10b5-1
  • May 15, 2026Carmen BozicEVP and CMO
    Kind10b5-1
  • May 15, 2026Mark E. BunnageEVP, Chief Scientific Officer
    Kind10b5-1
  • May 12, 2026Carmen BozicEVP and CMO
    Kind10b5-1
  • May 4, 2026Sangeeta N. Bhatia
    Kind10b5-1
  • May 1, 2026Joy LiuEVP and Chief Legal Officer
    Kind10b5-1
  • Apr 1, 2026Joy LiuEVP and Chief Legal Officer
    Kind10b5-1
  • Mar 27, 2026Carmen BozicEVP and CMO
    Kind10b5-1
  • Mar 13, 2026Carmen BozicEVP and CMO
    Kind10b5-1
  • Mar 11, 2026Duncan McKechnieEVP, Chief Commercial Officer
    Kind10b5-1

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 2, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by VRTX's officers and directors from 2004 up to November 15, 2025, 22 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

3 Holders over 5%May 14, 2026 Latest filing
  • Capital World Investors
    Share of class10.1%
  • Capital Research Global Investors
    Share of class8.30%
  • Vanguard Capital Management
    Share of class7.49%
Fell to 5% or less (2)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • The Vanguard Group0.00%Mar 27, 202613G/A
  • FMR3.60%Feb 12, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Renaissance Technologies
    In the quarter+24%
  • Millennium Mgmt (Englander)
    In the quarter×15.2
  • Citadel Advisors (Griffin)
    In the quarter+50%
  • AQR Capital
    In the quarter+260%
  • Bridgewater (Dalio)
    In the quarter-19%
  • Point72 (Cohen)
    In the quarter
  • D.E. Shaw
    In the quarter-99%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 1.68% of its shares outstanding were held short, -5.3% since the report before.

Shares held short
4.26M
1.68%
Since the report before4.50M on Sep 30, 2026
-5.3%
3.4
1.26M
More days to cover thanof 4,578 US-listed companies with enough volume
40%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 2.60M
  • Nov 15, 2023: Shares held short 2.51M
  • Nov 30, 2023: Shares held short 2.69M
  • Dec 15, 2023: Shares held short 3.55M
  • Dec 29, 2023: Shares held short 3.26M
  • Jan 12, 2024: Shares held short 3.35M
  • Jan 31, 2024: Shares held short 3.31M
  • Feb 15, 2024: Shares held short 4.13M
  • Feb 29, 2024: Shares held short 4.05M
  • Mar 15, 2024: Shares held short 4.13M
  • Mar 28, 2024: Shares held short 3.98M
  • Apr 15, 2024: Shares held short 4.03M
  • Apr 30, 2024: Shares held short 3.87M
  • May 15, 2024: Shares held short 3.77M
  • May 31, 2024: Shares held short 4.35M
  • Jun 14, 2024: Shares held short 4.47M
  • Jun 28, 2024: Shares held short 4.10M
  • Jul 15, 2024: Shares held short 4.12M
  • Jul 31, 2024: Shares held short 5.08M
  • Aug 15, 2024: Shares held short 4.42M
  • Aug 30, 2024: Shares held short 4.38M
  • Sep 13, 2024: Shares held short 4.34M
  • Sep 30, 2024: Shares held short 4.08M
  • Oct 15, 2024: Shares held short 4.29M
  • Oct 31, 2024: Shares held short 4.50M
  • Nov 15, 2024: Shares held short 4.11M
  • Nov 29, 2024: Shares held short 3.67M
  • Dec 13, 2024: Shares held short 3.51M
  • Dec 31, 2024: Shares held short 3.96M
  • Jan 15, 2025: Shares held short 4.39M
  • Jan 31, 2025: Shares held short 4.56M
  • Feb 14, 2025: Shares held short 5.07M
  • Feb 28, 2025: Shares held short 5.48M
  • Mar 14, 2025: Shares held short 5.75M
  • Mar 31, 2025: Shares held short 4.46M
  • Apr 15, 2025: Shares held short 4.37M
  • Apr 30, 2025: Shares held short 3.78M
  • May 15, 2025: Shares held short 4.82M
  • May 30, 2025: Shares held short 4.41M
  • Jun 13, 2025: Shares held short 4.03M
  • Jun 30, 2025: Shares held short 4.39M
  • Jul 15, 2025: Shares held short 4.19M
  • Jul 31, 2025: Shares held short 4.36M
  • Aug 15, 2025: Shares held short 3.70M
  • Aug 29, 2025: Shares held short 3.64M
  • Sep 15, 2025: Shares held short 4.05M
  • Sep 30, 2025: Shares held short 3.56M
  • Oct 15, 2025: Shares held short 3.56M
  • Oct 31, 2025: Shares held short 4.13M
  • Nov 14, 2025: Shares held short 4.01M
  • Nov 28, 2025: Shares held short 4.46M
  • Dec 15, 2025: Shares held short 4.29M
  • Dec 31, 2025: Shares held short 5.02M
  • Jan 15, 2026: Shares held short 4.42M
  • Jan 30, 2026: Shares held short 4.42M
  • Feb 13, 2026: Shares held short 4.47M
  • Feb 27, 2026: Shares held short 4.43M
  • Mar 13, 2026: Shares held short 4.13M
  • Mar 31, 2026: Shares held short 4.02M
  • Apr 15, 2026: Shares held short 4.34M
  • Apr 30, 2026: Shares held short 4.17M
  • May 15, 2026: Shares held short 4.46M
  • May 29, 2026: Shares held short 4.49M
  • Jun 15, 2026: Shares held short 4.62M
  • Jun 30, 2026: Shares held short 4.94M
  • Jul 15, 2026: Shares held short 4.99M
  • Jul 31, 2026: Shares held short 3.94M
  • Aug 14, 2026: Shares held short 4.15M
  • Aug 31, 2026: Shares held short 4.66M
  • Sep 15, 2026: Shares held short 4.72M
  • Sep 30, 2026: Shares held short 4.50M
  • Oct 15, 2026: Shares held short 4.26M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading60.9% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 60.9% of the shares in the reported trades were short sales, against 42.7% in the 14 before.

Last 14 sessionsOct 27, 2026 – Nov 13, 2026
60.9%
The 14 beforeOct 7, 2026 – Oct 26, 2026
42.7%
Change
+18.2 pts
Short sales a dayon average, of 559.2K shares
340.8K
More than atof 3,649 US-listed companies, same days
86%
Median of alleight in ten from 34.6% to 63.4%
50.1%
  • Oct 7, 2026: Short sales 54.6%
  • Oct 8, 2026: Short sales 42.5%
  • Oct 9, 2026: Short sales 31%
  • Oct 12, 2026: Short sales 36.6%
  • Oct 13, 2026: Short sales 59%
  • Oct 14, 2026: Short sales 40.4%
  • Oct 15, 2026: Short sales 29.9%
  • Oct 16, 2026: Short sales 40.1%
  • Oct 19, 2026: Short sales 29.3%
  • Oct 20, 2026: Short sales 29.2%
  • Oct 21, 2026: Short sales 50.9%
  • Oct 22, 2026: Short sales 64.5%
  • Oct 23, 2026: Short sales 58.4%
  • Oct 26, 2026: Short sales 55.3%
  • Oct 27, 2026: Short sales 49.4%
  • Oct 28, 2026: Short sales 66.5%
  • Oct 29, 2026: Short sales 61.4%
  • Oct 30, 2026: Short sales 71.7%
  • Nov 2, 2026: Short sales 70.4%
  • Nov 3, 2026: Short sales 60.1%
  • Nov 4, 2026: Short sales 58.1%
  • Nov 5, 2026: Short sales 63.1%
  • Nov 6, 2026: Short sales 52.9%
  • Nov 9, 2026: Short sales 46.9%
  • Nov 10, 2026: Short sales 54%
  • Nov 11, 2026: Short sales 43.8%
  • Nov 12, 2026: Short sales 60.2%
  • Nov 13, 2026: Short sales 45.3%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

549.8K Insiders' shares0.22% Of the company
  • Reshma KewalramaniCEO & President
    Directly86.5K
  • Jeffrey M LeidenExecutive Chairman
    Directly75.2K
  • Amit SachdevEVP Chief Patient & Ext Af Off
    Directly74.0K
  • Ourania TatsisEVP, Chief Reg. & Quality Off.
    Directly53.6K
  • Stuart A ArbuckleEVP, COO
    Directly49.7K
  • Bruce I SachsDirector
    Directly39.0K
  • Charles F Wagner JrEVP, CO & FO
    Directly37.7K
  • David AltshulerEVP, Chief Scientific Officer
    Directly23.3K
  • Joy LiuEVP and Chief Legal Officer
    Directly19.1K
  • Edward Morrow Atkinson IIIEVP, Chief Technical Ops. Off.
    Directly18.4K
  • Carmen BozicEVP and CMO
    Directly15.3K
  • Jonathan BillerEVP and Chief Legal Officer
    Directly13.7K
  • Kristen AmbroseSVP & Chief Accounting Officer
    Directly11.6K
  • Duncan McKechnieEVP, Chief Commercial Officer
    Directly11.0K
  • Grunsven Jasper vanEVP, CP and NPPO
    Directly8,682
  • Mark E. BunnageEVP, Chief Scientific Officer
    Directly7,284
  • Sangeeta N. BhatiaDirector
    Directly4,924
  • Daniel J. BrennanDirector
    Directly795

A lower bound: it counts only the 18 officers and directors with a market trade since Nov 17, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

10b5-1 trading plans

Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.

14 Adopted in the last 12 months15 Filings read
  • Alan GarberDirector
    What happenedAdoptedAug 27, 2026
    Shares5,320
  • Bruce SachsDirector
    What happenedAdoptedAug 26, 2026
    Shares9,888
  • Joy LiuEVP, Chief Legal Officer
    What happenedAdoptedAug 21, 2026
    Shares20.8K
  • Nancy ThornberryDirector
    What happenedAdoptedAug 15, 2026
    Shares2,571
  • Sangeeta BhatiaDirector
    What happenedAdoptedAug 13, 2026
    Shares1,189
  • Charles F. Wagner, Jr.EVP, Chief Operating & Financial Officer
    What happenedAdoptedAug 10, 2026
    Shares15.3K
  • Carmen BozicEVP, Global Medicines Development and Medical Affairs, and Chief Medical Officer
    What happenedAdoptedAug 6, 2026
    Shares16.9K
  • Kristen AmbroseSVP, Chief Accounting Officer
    What happenedAdoptedAug 6, 2026
    Shares5,422
  • Jeffrey LeidenExecutive Chairman
    What happenedAdoptedAug 5, 2026
    Shares18.4K
  • Reshma KewalramaniChief Executive Officer and President, Director
    What happenedAdoptedAug 5, 2026
    Shares47.8K

As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.

Executive pay

From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.

2025 Latest year6 Years on record

$21M

Actually paid: $38M

$7.7M

Actually paid: $13M

$192

Peers: $125

net product revenue

$12.0B

From the proxy statement (DEF 14A) of Apr 2, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A

Share repurchases

How many of its own shares the company bought each quarter, at what average price, for how much, and what remains of the program its board authorized, from the table it puts in every 10-Q and 10-K.

$2.0B Repurchases over 4 quarters$2.6B Left in the program
  • Jun 30, 202610-Q
    Amount$455M
  • Mar 31, 202610-Q
    Amount$344M
  • Dec 31, 202510-K
    Amount$105M
  • Sep 30, 202510-Q
    Amount$1.1B
  • Jun 30, 202510-Q
    Amount$395M
  • Mar 31, 202510-Q
    Amount$417M
  • Dec 31, 202410-K
    Amount$427M
  • Sep 30, 202410-Q
    Amount$308M

From the "Issuer Purchases of Equity Securities" table of the 10-Qs and 10-Ks, read without a model. Only the quarters whose shares times average price agree with the cash the company says it paid for repurchases in its cash-flow statement are shown. The shares include those withheld for officers' taxes. A quarter with an accelerated repurchase shows the table's shares and the cash paid, without an average price. 1 filing(s) not shown, as the table was not read or did not agree with the cash.

The shareholders' vote on pay

The advisory say-on-pay vote at each annual meeting, as the company states it in the 8-K it files after the meeting: how many voted for and against the executives' pay. 90% is the norm. Under 70% proxy advisers expect the board to respond the next year.

93.5% For in 20266 Votes on record
  • 2026May 13, 2026
    For
    93.5%
  • 2025May 14, 2025
    For
    92.5%
  • 2024May 15, 2024
    For
    91.3%
  • 2023May 18, 2023
    For
    89.5%
  • 2022May 18, 2022
    For
    92.6%
  • 2021May 19, 2021
    For
    91.4%

From the 8-K (item 5.07) the company files after each annual meeting since 2021, read from the filing's text without a model. A company that votes every three years has empty years. The vote is advisory: the board is not bound by it.

The ETFs that hold it

Which of the 269 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

48 ETFs holding it8.08% The largest weight (IBB)
  • IBBiShares Biotechnology ETF
    Weight in the fund8.08%
  • XLVState Street(R) Health Care Select Sector SPDR(R) ETF
    Weight in the fund2.19%
  • CGGRCapital Group Growth ETF
    Weight in the fund2.03%
  • IYHiShares U.S. Healthcare ETF
    Weight in the fund2.00%
  • VHTVanguard Health Care Index Fund
    Weight in the fund1.92%
  • CGUSCapital Group Core Equity ETF
    Weight in the fund1.90%
  • IXJiShares Global Healthcare ETF
    Weight in the fund1.64%
  • CGGOCapital Group Global Growth Equity ETF
    Weight in the fund1.62%
  • USMViShares MSCI USA Min Vol Factor ETF
    Weight in the fund1.46%
  • CGBLCapital Group Core Balanced ETF
    Weight in the fund1.20%

48 of the 269 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

1,756 Managers, Q2 2026$120B Value of their positions
  • Q3 2025: Managers 1,523
  • Q4 2025: Managers 1,671
  • Q1 2026: Managers 1,701
  • Q2 2026: Managers 1,756

Institutional investors by quarter

The fund managers holding VRTX, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 1,756 managers held 242M shares, worth $120B. During the quarter 192 opened a position, 137 closed one, 697 added and 610 trimmed.

The largest holders, Q2 2026

  • Capital World Investors
    In the quarter+2.9%
  • BlackRock
    In the quarter+0.6%
  • Capital Research Global Investors
    In the quarter-7.7%
  • Vanguard Capital Management
    In the quarter+0.4%
  • State Street
    In the quarter+1.2%
  • Invesco
    In the quarter+1.9%
  • JPMorgan Chase
    In the quarter-7.3%
  • Geode Capital Management
    In the quarter-2.0%
  • Vanguard Portfolio Management
    In the quarter-5.2%
  • Capital International Investors
    In the quarter-8.4%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

The full analysis

What do Vertex Pharmaceuticals's filings show?

Who buys and sells is one part of Vertex Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about VRTX's shareholders

Didn't find what you were looking for?

Ask us
Have VRTX's insiders bought or sold?

From Jun 2, 2026 to Nov 10, 2026 Vertex Pharmaceuticals's insiders bought 0 and sold $13M of shares on the market. 100% of the sales were under set 10b5-1 plans.

Which well-known managers hold VRTX?

7 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $305M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.